甘露消毒丹及其拆方对肺炎支原体干预的NR8383细胞炎症因子表达的影响

doi:10.20047/j.issn1673-7210.2023.18.01

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (1492 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of Ganlu Xiaodu Micropills and its decoction on the expression of inflammatory factors in rat alveolar macrophages (NR8383) infected with Mycoplasma pneumoniae (MP). Methods Thirty-five female Wistar rats of SPF grade aged eight weeks, weighing (200±10) g, were selected. According to the random number table method, they were divided into blank serum group (normal saline 2 ml/d), Ganlu Xiaodu Micropills serum group (33 g/[kg·d]), Azithromycin serum group (0.063 mg/[kg·d]), decoction part 1 serum group (12.3 g/[kg·d]), decoction part 2 serum group (20.8 g/[kg·d]), with seven rats in each group. Each group of doses was given once a day for one week to prepare drug- containing serum. NR8383 cells were treated with blank serum and drug-containing serum, respectively, CCK-8 assay was used to detect and compare the difference of viability between NR8383 cells treated with different serum and untreated cells. NR8383 cells were divided into control group, model group, Ganlu Xiaodu Micropills group, Azithromycin group, and decoction part 1, 2 groups. Except for the control group, the other groups were treated with 106-107 CCU/ml MP bacterial solution for four hours to establish MP infection model, and then the corresponding drug-containing serum was added and incubated for 24 hours. The cells and supernatant were collected, and qPCR and Western blot were used to detect the mRNA and protein expression of Toll-like receptor 4 (TLR4), MyD88, and nuclear factor κB (NF-κB) in each group. The expression levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-10 in each group were detected by enzyme-linked immunosorbent assay. Results The survival rate of cells treated with each serum were lower than those of cells without treatment (P＜0.05). There was no significant difference in the survival rate of cells treated with different serum (P＞0.05). The expression levels of TLR4, MyD88, and NF-κB-p50 mRNA and protein in the model group were higher than those in the control group, and the expression levels of TLR4, MyD88, and NF-κB-p50 mRNA and protein in the Ganlu Xiaodu Micropills group and the decoction part 2 group were lower than those in the model group, the expression of MyD88 mRNA and TLR4 protein in the decoction part were lower than those in the model group (P＜0.05). The mRNA expression of TLR4 and MyD88, and the protein levels of TLR4, MyD88, NF-κB-p50 in Ganlu Xiaodu Micropills group were lower than those in decoction part 1 group, and the mRNA expression of NF-κB-p50 and the protein level of TLR4 were higher than those in decoction part 2 group (P＜0.05). The levels of TNF-α and IL-1β in Ganlu Xiaodu Micropills group and decoction part 2 group were lower than those in model group, the level of IL-1β in decoction part 1 group was lower than that in model group, and the level of IL-10 in decoction part 2 group was lower than that in model group (P＜0.05). The levels of TNF-α, IL-1β, and IL-10 in Ganlu Xiaodu Micropills group were lower than those in decoction part 1 group, and the levels of TNF-α and IL-1β were higher than those in decoction part 2 group (P＜0.05). Conclusion MP infection can promote the expression of TNF-α, IL-1β, and IL-10 in NR8383 cells. Ganlu Xiaodu Micropills and its decoction containing serum can reduce the inflammatory response by inhibiting the expression of TNF-α and IL-1β, and the mechanism may be related to the TLR4/MyD88/NF-κB pathway.

Key words： Ganlu Xiaodu Micropills Mycoplasma pneumoniae Rat alveolar macrophage Tumor necrosis factor-α Interleukin-1β Interleukin-10

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Hao1 ZHANG Baoqing2▲ ZHOU Xu2

Cite this article:

ZHENG Hao1 ZHANG Baoqing2▲ ZHOU Xu2. Effect of Ganlu Xiaodu Micropills and its decoction parts on the expression of inflammatory factors in NR8383 cells treated with Mycoplasma pneumoniae[J]. 中国医药导报, 2023, 20(18): 4-9.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.18.01 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I18/4

[1] Gao LW，Yin J，Hu YH，et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China：2006 to 2016 [J]. Epidemiol Infect，2019，147：e192.
[2] Krafft C，Christy C. Mycoplasma Pneumonia in Children and Adolescents [J]. Pediatr Rev，2020，41（1）：12-19.
[3] Tong L，Huang S，Zheng C，et al. Refractory Mycoplasma pn- eumoniae Pneumonia in Children：Early Recognition and Management [J]. J Clin Med，2022，11（10）：2824.
[4] Dai FF，Liu FQ，Chen X，et al. The treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children [J]. J Clin Pharm Ther，2021，46（3）：705-710.
[5] 魏岩，马金玲，马丹，等.治疫名方甘露消毒丹证治探微[J].长春中医药大学学报，2022，38（3）：241-244.
[6] 王晓，贺红安，张葆青.基于网络药理学和分子对接探讨甘露消毒丹治疗肺炎支原体肺炎的机制[J].中国现代应用药学，2022，39（3）：343-351.
[7] 贺红安.祛湿通络方含药血清对RAW264.7细胞miR-155、miR-146a表达的影响及临床研究[D].济南：山东中医药大学，2021.
[8] 杨帆，王欣，班谨政.肺炎支原体菌株纯度和浓度鉴定[J].黑龙江中医药，2021，50（2）：418-419.
[9] 贺红安，张葆青，王晓，等.小儿难治性肺炎支原体肺炎中医研究概述[J].山东中医杂志，2021，40（3）：319-323.
[10] 杨会荣，张应谦，黄坤玲，等.清热解毒方佐治痰热闭肺型难治性肺炎支原体肺炎临床效果[J].中国医药导报，2022，19（14）：146-149.
[11] 孙丹，李新民，路岩莉，等.小儿支原体肺炎的中医证候演变规律研究进展[J].中医儿科杂志，2019，15（5）：94-96.
[12] 路瑞静，王丰，周坤朋，等.2017—2019年深圳市宝安区儿童肺炎支原体呼吸道感染的流行病学特征分析[J].实用预防医学，2020，27（11）：1353-1355.
[13] 李新民，马莉婷，孙丹，等.小儿肺炎喘嗽湿热内蕴证证治探讨[J].中华中医药杂志，2018，33（11）：5117-5121.
[14] 周朋，周旭，张葆青.儿童难治性支原体肺炎发病机制研究进展[J].山东医药，2016，56（42）：103-105.
[15] 李娜，于光志，张葆青，等.祛湿通络方对肺炎支原体感染的RAW264.7细胞TNF-α、IL-6表达的影响[J].天津中医药大学学报，2020，39（5）：564-569.
[16] Gabay C，Lamacchia C，Palmer G. IL-1 pathways in inflammation and human diseases [J]. Nat Rev Rheumatol，2010，6（4）：232-241.
[17] Ma B，Athari SS，Mehrabi NE，et al. PI3K/AKT/mTOR and TLR4/MyD88/NF-κB Signaling Inhibitors Attenuate Patho- logical Mechanisms of Allergic Asthma [J]. Inflammation，2021，44（5）：1895-1907.
[18] Jiang Z，Li S，Zhu C，et al. Mycoplasma pneumoniae Infections：Pathogenesis and Vaccine Development [J]. Pathogens， 2021，10（2）：119.
[19] Tian F，Chen LP，Yuan G，et al. Differences of TNF-α，IL-6 and Gal-3 in lobar pneumonia and bronchial pneumonia caused by mycoplasma pneumoniae [J]. Technol Health Care，2020，28（6）：711-719.
[20] 张超，吕国峰，王沂霞，等.TNF-α基因多态性与儿童支原体肺炎病情程度的关联性[J].中华医院感染学杂志，2021，31（21）：3342-3345.
[21] 凌小艳.支气管哮喘合并肺炎支原体感染患儿血浆内皮素1及肿瘤坏死因子α水平与疾病严重程度的相关性研究[J].中国医药，2021，16（8）：1172-1175.
[22] Su X，You X，Luo H，et al. Community-Acquired Respiratory Distress Syndrome Toxin：Unique Exotoxin for M. pneumoniae [J]. Front Microbiol，2021，12：766591.
[23] 王庆.血清IL-1β、IL-18在儿童支原体肺炎中的表达及意义[D].唐山：华北理工大学，2021.
[24] Saraiva M，Vieira P，O’Garra A. Biology and therapeutic potential of interleukin-10 [J]. J Exp Med，2020，217（1）：e20190418.
[25] Neumann C，Scheffold A，Rutz S. Functions and regulation of T cell-derived interleukin-10 [J]. Semin Immunol，2019， 44：101344.
[26] 董艳艳，张广超.麻杏石甘汤对小儿支原体肺炎血清炎性因子水平及临床疗效的影响[J].山西医药杂志，2021，50（22）：3108-3110.
[27] 叶新明，钱克俭.重症肺炎支原体肺炎肺泡灌洗液中TNF-α、IL-6、IL-8、IL-10水平观察[J].南昌大学学报（医学版），2010，50（4）：72-74.
[28] Wang X，Zhong LJ，Chen ZM，et al. Necrotizing pneumonia caused by refractory Mycoplasma pneumonia pneumonia in children [J]. World J Pediatr，2018，14（4）：344-349.